Inhalers whose patents were deemed improperly listed in the Orange Book by the Federal Trade Commission have retained market dominance with their device components. • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
